Sonoma Pharmaceuticals, Inc. (SNOA) company profile
Close on Nov 17, 2026Market cap $3.99MP/E –Yield –
About Sonoma Pharmaceuticals
Surgical & Medical Instruments & Apparatus, SIC 3841
Sonoma Pharmaceuticals, Inc. develops and manufactures stabilized hypochlorous acid products across six primary business channels: wound care, dermatology, eye care, podiatry, animal health care, and non-toxic surface disinfectants. Its offerings include prescription, over-the-counter, and office-dispense topical solutions, hydrogels, sprays, and cleansers designed to alleviate pain, itch, redness, and scarring while supporting skin and wound healing. The company distributes its medical device solutions directly and through commercial partners to hospitals, physicians, retail pharmacy chains, pet specialty stores, and everyday consumers.
The company operates internationally, commercializing products directly or through distribution partnerships across more than 55 countries worldwide, including the United States, Europe, Asia, and Latin America. All manufacturing activities take place at a dedicated production facility located in Zapopan, Mexico. Sonoma Pharmaceuticals maintains corporate headquarters in Boulder, Colorado, with additional operational entities based in the Netherlands.
Summary of the business section of Sonoma Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Sonoma Pharmaceuticals, Inc.
- Founded
- 1999
- Headquarters
- Boulder, CO
- Address
- 5445 Conestoga Court, Suite 150 80301
- Phone
- (800) 759-9305
- Website
- sonomapharma.com
- Employees
- 250, Mar 31, 2026
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- March 31
- Auditor
- Frazier & Deeter, LLC, Nashville, Tennessee
Stock & identifiers
- Ticker
- SNOA
- Former tickers
- OCLS until Aug 16, 2021
- Exchange
- Nasdaq
- IPO date
- Jan 26, 2007
- Shares outstanding
- 5M, Aug 6, 2026
- Public float
- $6.32M, Sep 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Aug 30, 2024; 1-for-9 reverse, Jun 20, 2019; 1-for-5 reverse, Jun 27, 2016; 1-for-7 reverse, Apr 1, 2013
- SEC CIK
- 1367083
- CUSIP
- 83558L303
- ISIN
- US83558L3033
- FIGI
- BBG000M75YR0
- Share class FIGI
- BBG001SQ8K88
- LEI
- 54930008C5Z4F02SWO71
- EIN
- 68-0423298
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Poggetto John Dal | Controller | 15,000 |
| Amy Moss Trombly | Chief Executive Officer | 153,586 |
| Jerome J. Dvonch | Chief Financial Officer | 84,595 |
| Bruce Thornton | Executive VP and COO | 154,411 |
| Vanessa Jacoby | Director | – |
| John McLaughlin | Director | 48,728 |
| Philippe Weigerstorfer | Director | 22,500 |
| Jay E. Birnbaum | Director | 51,659 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 | $741.12K | $641.73K | $411.16K | $11 | – |
| FY2025 | $597.08K | $553.87K | $444.95K | $11 | – |
| FY2024 | $726.54K | $697.36K | $483.06K | $17 | – |
| FY2023 | $559.94K | $509.83K | $299.23K | $24 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2026
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Amy Trombly Chief Executive Officer | $407.50K | $195.00K | $74.88K | $63.74K | $741.12K | +24% |
| Jerry Dvonch Chief Financial Officer | $240.00K | $60.00K | $56.68K | $66.00K | $422.68K | +18% |
| Bruce Thornton Former Executive Vice President and Chief Operating Officer | $170.50K | $156.48K | $38.48K | $34.18K | $399.64K | -25% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jan 26, 2007
- Offer price
- $8.00
- Securities offered
- 3,025,000
- Gross proceeds
- $24.20M
- Exchange
- Nasdaq
- First trading day
- Jan 25, 2007
- First-day close
- $7.80-2.5%
- Lock-up ends (est.)
- Jul 24, 2007
“Per Share Total Public offering price $ 8.00 $ 24,200,000 Underwriting discount $ 0.56 $ 1,694,000 Proceeds, before expenses, to Oculus Innovative Sciences, Inc.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“Additionally, we had approximately 250 employees in Mexico.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?